Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 2/20 | 0.73 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 11/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062102 | 0.91 | MAP3K7 (0.61) | MAP3K7TAB1BRAFAURKAAXL | |
| SCHEMBL5066510 | 0.90 | MAP3K7 (0.78) | MAP3K7TAB1BRAFAURKARAF1 | |
| SCHEMBL5062813 | 0.89 | MAP3K7 (0.56) | MAP3K7BRAFAXLCSF1RPDGFRB | |
| SCHEMBL5058615 | 0.88 | MAP3K7 (0.75) | MAP3K7TAB1BRAFAURKARAF1 | |
| SCHEMBL573733 | 0.85 | KDR (0.59) | MAP3K7BRAFAXLRAF1CSF1R | |
| SCHEMBL5060337 | 0.85 | MAPK14 (0.60) | MAP3K7BRAFAXLRAF1CSF1R | |
| SCHEMBL23610620 | 0.85 | MAP3K7 (1.00) | MAP3K7TAB1BRAFAURKARAF1 | |
| SCHEMBL30673965 | 0.85 | MAP3K7 (1.00) | MAP3K7TAB1BRAFAURKARAF1 | |
| Hydrochloric Acid SCHEMBL5063078 | 0.84 | MAPK14 (0.60) | MAP3K7BRAFAXLRAF1CSF1R | |
| SCHEMBL5052111 | 0.84 | MAPK13 (0.57) | MAP3K7BRAFAXLRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | MAP3K7 59/4885TAB1 541/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.